Date of SOH Approval: 26 August 2022
Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of Second Booster of COVID-19 vaccines for the prevention of COVID-19 among individuals aged 50 years old and older and individuals with comorbidities aged 18 to 49 years old. This assessment follows the HTAC evaluation framework to assess COVID-19 vaccines using the following criteria: (1) responsiveness to magnitude and severity; (2) clinical efficacy and safety; (3) affordability and viability; (4) household financial impact; (5) social impact; and (6) responsiveness to equity.
HTAC Recommendation Preview:
